rethinkPeptides Search
Menu
Research citation

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Lancet (London, England), 394(10193), 121-130

Citation

Gerstein, Hertzel C; Colhoun, Helen M; Dagenais, Gilles R; Diaz, Rafael; Lakshmanan, Mark; Pais, Prem; Probstfield, Jeffrey; Riesmeyer, Jeffrey S; Riddle, Matthew C; Rydén, Lars; Xavier, Denis; Atisso, Charles Messan; Dyal, Leanne; Hall, Stephanie; Rao-Melacini, Purnima; Wong, Gloria; Avezum, Alvaro; Basile, Jan; Chung, Namsik; Conget, Ignacio; Cushman, William C; Franek, Edward; Hancu, Nicolae; Hanefeld, Markolf; Holt, Shaun; Jansky, Petr; Keltai, Matyas; Lanas, Fernando; Leiter, Lawrence A; Lopez-Jaramillo, Patricio; Cardona Munoz, Ernesto German; Pirags, Valdis; Pogosova, Nana; Raubenheimer, Peter J; Shaw, Jonathan E; Sheu, Wayne H-H; Temelkova-Kurktschiev, Theodora. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.. Lancet (London, England), 394(10193), 121-130. https://doi.org/10.1016/S0140-6736(19)31149-3